natgillin/translations-raw huggingface dataset:
Samtidig anvendelse af cochicin og boostet darunavir kan øge eksponeringen for colchicin.
Concomitant use of colchicine and boosted darunavir may increase the exposure to colchicine.
Brug af boostet darunavir sammen med disse antikoagulantia frarådes.
The use of boosted darunavir and these anticoagulants is not recommended.
(til behandling af depression og angst) - Maraviroc (til hiv-infektion) - Methadon (til behandling af opioidafhængighed) - Carbamazepin, clonazepam (til forebyggelse af krampeanfald eller til behandling af visse typer nervesmerter) - Colchicin (til behandling af urinsur gigt eller familiær middelhavsfeber) - Bosentan (til behandling af for højt blodtryk i lungekredsløbet) - Buspiron, clorazepat, diazepam, estazolam, flurazepam, midazolam, når det tages som injektion, zoldipem (beroligende midler) - Perphenazin, risperidon, thioridazin (til behandling af psykiske lidelser) - Metformin (til behandling af type 2-diabetes).
Carbamazepine, clonazepam(to prevent seizures or to treat certain types of nerve pain) Colchicine (to treat gout or familial Mediterranean fever) Bosentan (to treat high blood pressure in the pulmonary circulation) Buspirone, clorazepate, diazepam, estazolam, flurazepam, midazolam when used as injection, zoldipem (sedative agents)
Samtidig anvendelse af salmeterol og boostet darunavir kan øge plasmakoncentrationen af salmeterol.
Concomitant use of salmeterol and boosted darunavir may increase plasma concentrations of salmeterol.
Coadministration af darunavir og ritonavir med lægemidler, som primært metaboliseres af CYP2D6 (såsom flecainid, propafenon, metoprolol), kan resultere i en øget plasmakoncentration af disse lægemidler, hvilket kan øge eller forlænge deres terapeutiske effekt og bivirkninger.
Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
≥15 kg-<30 kg 600 mg darunavir/100 mg ritonavir en gang dagligt
≥ 15 kg-< 30 kg 600 mg darunavir/100 mg ritonavir once daily
Hud og subkutane væv almindelig udslæt (herunder makuløst, makulopapuløst, papuløst, erytematøst og kløende udslæt), pruritus ikke almindelig angioødem, generaliseret udslæt, allergisk dermatitis, urticaria, eksem, erytem, hyperhidrose, nattesved, alopeci, akne, tør hud, neglepigmentering sjælden
Skin and subcutaneous tissue disorders common rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus uncommon angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation rare
600 mg en gang daglig efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz fra CYP3Ahæmning) (↓ darunavir fra CYP3Ainduktion)
600 mg once daily efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction)
Hver filmovertrukken tablet indeholder 400 mg eller 800 mg darunavir.
Each film-coated tablet contains 400 mg or 800 mg darunavir.
Metabolisme og ernæring almindelig diabetes mellitus, hypertriglyceridæmi, hyperkolesterolæmi, hyperlipidæmi ikke almindelig artritis urica, anoreksi, nedsat appetit, vægttab, vægtstigning, hyperglykæmi, insulinresistens, nedsat HDL, øget appetit, polydipsi, øget lactatdehydrogenase i blodet
Metabolism and nutrition disorders common diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia uncommon gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
Patientandelen (%)med respons(hiv-1-RNA < 50 kopier/ml ved uge 24) over for darunavir co-administreret med ritonavir (600/100 mg to gange dagligt) efter genotype ved baselinea og darunavir FC ved baseline og efter brug af enfuvirtid (ENF): ”As treated-analyse” af POWER- og DUET-studierne.
Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to darunavir coadministered with ritonavir (600/100 mg twice daily) by baseline genotype a, and baseline darunavir
Der skal udvises forsigtighed, når clarithromycin kombineres med darunavir administreret sammen med lavdosis ritonavir.
Caution should be exercised when clarithromycin is combined with darunavir co-administered with low dose ritonavir.
Baseret på teoretiske overvejelser forventes coadministreret boostet darunavir at øge eksponeringen for lomitapid.
Based on theoretical considerations boosted darunavir is expected to increase the exposure of lomitapide when coadministered.
Dosis til voksne, som tidligere har fået hiv-medicin (din læge vil afgøre dette)
in certain patients who have used antiretroviral medicines before (your doctor will determine this).
Den anbefalede dosis er 800 mg en gang dagligt sammen med ritonavir 100 mg en gang dagligt i forbindelse med et måltid.
The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.
Et dosisregime med darunavir taget med ritonavir en gang dagligt i forbindelse med et måltid kan anvendes til patienter, der tidligere har været eksponeret for antiretrovirale lægemidler, men uden mutationer associeret med darunavirresistens (DRV-RAMs)*, og som har plasma-hiv-1-RNA < 100.000 kopier/ml og CD4+-celletal  100 x 10 celler /l.
A once daily dose regimen of darunavir taken with ritonavir taken with food may be used in patients with prior exposure to antiretroviral medicinal products but without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Darunavir Krka kan muligvis øge risikoen for forhøjet kaliumindhold i blodet pga. drospirenon.
Darunavir Krka might increase the risk for elevated potassium levels by drospirenone.
I andet trimester af graviditeten var værdierne for Cmax, AUC24t og Cmin for cobicistat hhv. 50 %, 63 % og 83 % lavere i forhold til post partum.
During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%, 63%, and 83% lower, respectively, as compared with postpartum.
Lopinavir/ritonavir 533/133,3 mg to gange daglig lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38%‡ darunavir Cmin ↓ 51%‡ darunavir Cmax ↓ 21%‡ lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% baseret på ikkedosisnormaliserede værdier
Lopinavir/ritonavir 533/133.3 mg twice daily lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% based upon non dose normalised values
Der er kun begrænset erfaring med akut overdosering af darunavir, co-administreret med cobicistat eller lavdosis ritonavir, hos mennesker.
Human experience of acute overdose with darunavir co-administered with cobicistat or low dose ritonavir is limited.
Post partum (6-12 uger) (n=12)
Postpartum (6-12 weeks) (n=12)
Samtidig administration af
Method of administration
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-naive patienter
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ARTnaïve patients
Darunavir Krka, anvendes til behandling af hiv-infektion (hiv: humant immundefektvirus).
Darunavir Krka is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV) infection.
Co-administration af darunavir co-administreret med cobicistat og bosentan frarådes.
Co administration of darunavir coadministered with cobicistat and bosentan is not recommended.
I tredje trimester af graviditeten var værdierne for Cmax, AUC24t og Cmin for cobicistat hhv. 27 %, 49 % og 83 % lavere i forhold til post partum.
During the third trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin, were 27%, 49%, and 83% lower, respectively, as compared with postpartum.
Kombinationen af rifapentin og darunavir med samtidig lavdosis ritonavir frarådes.
The combination of rifapentine and darunavir with concomitant low dose ritonavir is not recommended.
Knogler, led, muskler og bindevæv ikke almindelig myalgi, osteonekrose, muskelspasmer, muskelsvaghed, artralgi, smerter i ekstremiteter, osteoporose, forhøjet kreatinphospho-kinase i blodet sjælden stivhed i skeletmuskulaturen, artritis, ledstivhed
Musculoskeletal and connective tissue disorders uncommon myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremity, osteoporosis, increased blood creatine phosphokinase rare musculoskeletal stiffness, arthritis, joint stiffness
Adskillige af interaktionsstudierne (markeret med # i tabellen nedenfor) er gennemført med doser af darunavir, der er lavere end de anbefalede doser, eller med et andet doseringsregime (se pkt.
# in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Anvisninger for voksne - Tag hver dag 2 tabletter på 400 mg på samme tidspunkt, eller 1 tablet på 800
Take two 400 milligram tablets at the same time or one 800 miligram tablet, once a day, every day.
450 mg Darunavir Krka + 60 mg ritonavir to gange dagligt mere end 40 kg*
450 milligram darunavir + 60 milligram ritonavir twice a day more than 40 kilograms*
600 mg darunavir/100 mg ritonavir to gange dagligt ritonavir oral opløsning: 80 mg/ml
600 mg darunavir /100 mg ritonavir twice daily with ritonavir oral solution: 80 mg/ml
Lopinavir/ritonavir 400/100 mg to gange daglig + OBR N=297
Lopinavir/ritonavir 400/100 mg twice daily + OBR N=297
Dosering to gange dagligt
Twice daily dosing Weight
Samtidig brug af darunavir med lavdosis ritonavir og elbasvir/grazoprevir er kontraindiceret (se pkt.
Concomitant use of darunavir with low dose ritonavir and elbasvir/grazoprevir is contraindicated (see section 4.3).
(CYP3A, CYP2D6 og/eller Pgp-hæmning)
(CYP3A, CYP2D6 and/or P-gp inhibition)
Det anbefales at bruge andre eller supplerende svangerskabsforebyggende metoder, når østrogenbaserede kontraceptiva gives sammen med boostet darunavir.
Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered
Produktresuméet for ritonavir skal derfor læses, inden behandling med darunavir påbegyndes.
The Summary of Product Characteristics of ritonavir must, therefore, be consulted prior to initiation of therapy with darunavir.
21 ART-erfarne hiv-1-smittede pædiatriske patienter i alderen 3 til <6 år med en legemsvægt på 10 kg til <20 kg (16 deltagere fra 15 kg til <20 kg) som fik darunavir oral suspension med lavdosis ritonavir to gange daglig i kombination med andre antiretrovirale lægemidler.
21 ART-experienced HIV-1 infected paediatric patients aged from 3 to < 6 years and weighing 10 kg to < 20 kg (16 participants from 15 kg to < 20 kg) who received darunavir oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents.
Darunavir Krka kan nedsætte virkningen af disse.
Darunavir Krka might reduce its effectiveness.
Samtidig anvendelse af bosentan og boostet darunavir kan øge plasmakoncentrationen af bosentan.
Concomitant use of bosentan and boosted darunavir may increase plasma concentrations of bosentan.
Plasmakoncentrationen af lovastatin og simvastatin forventes at stige markant, når de gives sammen med boostet darunavir.
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with boosted darunavir.
Antal deltagere med virologisk svigt og parrede fænotyper ved baseline/endepunkt, der udviste tab af følsomhed over for PI'er ved endepunktet sammenlignet med baseline, n/N
Number of subjects with virologic failure and paired baseline/endpoint phenotypes, showing loss of susceptibility to PIs at endpoint compared to baseline, n/N PI darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir
Almene symptomer og reaktioner på administrationsstedet almindelig asteni, træthed ikke almindelig pyrexi, brystsmerter, perifert ødem, utilpashed, varmefølelse, irritabilitet, smerte sjælden kulderystelse, unormal følelse, tørhed
General disorders and administration site conditions common asthenia, fatigue uncommon pyrexia, chest pain, peripheral oedema, malaise, feeling hot, irritability, pain rare chills, abnormal feeling, xerosis
Samtidig administration af darunavir med lavdosis ritonavir og lurasidon, pimozid eller sertindol er kontraindiceret (se pkt.
Concominant administration of darunavir with low dose ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Samtidig systemisk brug af clotrimazol og darunavir med samtidigt administreret lavdosis ritonavir kan øge plasmakoncentrationen af darunavir og/eller clotrimazol.
Concomitant systemic use of clotrimazole and darunavir co-administered with low dose ritonavir may increase plasma concentrations of darunavir and/or clotrimazole.
Mave-tarm-kanalen meget almindelig diarré almindelig opkastning, kvalme, abdominale smerter, forhøjet blodamylase, dyspepsi, abdominal distention, flatulens ikke almindelig pankreatitis, gastritis, gastroøsofageal reflukssygdom, aftøs stomatitis, opkastningsfornemmelser, mundtørhed, mavebesvær, forstoppelse, forhøjet lipase, ræben, oral dysæstesi sjælden stomatitis, hæmatemese, keilit, tørre læber, belægninger på tungen
Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence uncommon pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia rare stomatitis, haematemesis, cheilitis, dry lip, coated tongue
Andre kortikosteroider:
CORTICOSTEROIDS
Boostet darunavir må ikke anvendes samtidig med produkter, der indeholder perikon (Hypericum perforatum) (se pkt.
Boosted darunavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3).
Co-administration af darunavir, lavdosis ritonavir og sildenafil til behandling af pulmonal arteriel hypertension er derfor kontraindiceret (se pkt.
Therefore, co-administration of darunavir with low dose ritonavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).
Den sædvanlige dosis af Darunavir Krka er 800 mg (2 tabletter a 400 mg Darunavir Krka eller 1 tablet a 800 mg Darunavir Krka) en gang dagligt.
The usual dose of Darunavir Krka is 800 milligram (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) once daily.
Der er ikke behov for dosisjustering hos patienter med nedsat nyrefunktion (se pkt.
Renal impairment No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).
ELLER - 600 mg Darunavir Krka (1 tablet a 600 mg Darunavir Krka) sammen med 100 mg ritonavir to gange dagligt.
600 milligram Darunavir Krka (1 tablet containing 600 milligram of Darunavir Krka) together with 100 milligram ritonavir twice daily.
Samtidig brug af boostet darunavir og elbasvir/grazoprevir er kontraindiceret (se pkt.
Concomitant use of boosted darunavir and elbasvir/grazoprevir is contraindicated (see section 4.3).
En sikker og effektiv dosis af sildenafil til behandling af pulmonal arteriel hypertension administreret sammen med darunavir og lavdosis ritonavir.er ikke fastlagt.
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with darunavir and low dose ritonavir has not been established.
Samtidig administration af boostet darunavir og lurasidon, pimozid eller sertindol er kontraindiceret (se pkt.
Concominant administration of boosted darunavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Klinisk monitoring anbefales ved administration af boostet darunavir og lavdosis ritonavir sammen med disse analgetika.
Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir with these analgesics.
Darunavir bør ikke anvendes til pædiatriske patienter under 3 år eller med en legemsvægt under 15 kg (se pkt.
Darunavir should not be used in paediatric patients below 3 years of age or less than 15 kg body weight (see sections 4.4 and 5.3).
Darunavir Krka 800 mg filmovertrukne tabletter (tabletter):
Darunavir Krka 800 mg film-coated tablets (tablets):
Luftveje, thorax og mediastinum ikke almindelig dyspnø, hoste, næseblødning, halsirritation sjælden næseflåd
Respiratory, thoracic and mediastinal disorders uncommon dyspnoea, cough, epistaxis, throat irritation rare rhinorrhoea
Darunavir Krka 400 mg og 800 mg tabletter kan anvendes til at sammensætte regimet med 800 mg en gang dagligt.
Darunavir Krka 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.
Samtidig systemisk brug af clotrimazol og boostet darunavir kan øge plasmakoncentrationen af darunavir og/eller clotrimazol.
Concomitant systemic use of clotrimazole and boosted darunavir may increase plasma concentrations of darunavir and/or clotrimazole.
Samtidig anvendelse af salmeterol og darunavir administreret sammen med lavdosis ritonavir anbefales ikke.
Concomitant use of salmeterol and darunavir co-administered with low dose ritonavir is not recommended.
Ved 48 uger blev non-inferioritet i virologisk respons over for darunavir/ritonavirbehandlingen, defineret som procentdelen af patienter med plasma hiv-1-RNA-niveau < 400 og < 50 kopier/ml, påvist (ved den forud definerede 12 % grænse for noninferioritet) hos begge populationer (”Intent-To-Treat” og ”On Protocol”).
At 48 weeks non-inferiority in virologic response to the darunavir/ritonavir treatment, defined as the percentage of patients with plasma HIV-1 RNA level < 400 and < 50 copies/ml, was demonstrated (at the pre-defined 12% non-inferiority margin) for both ITT and OP populations.
Darunavir anbefales ikke til brug til pædiatriske patienter under 3 år eller med en legemsvægt under 15 kg (se pkt.
Darunavir is not recommended for use in paediatric patients below 3 years of age or less than 15 kg body weight (see sections 4.2 and 5.3).
Rifapentin og rifampicin er potente CYP3Ainduktorer, som er vist at forårsage et væsentligt fald i koncentrationen af andre proteasehæmmere.
Rifapentine and rifampicin are strong CYP3A inducers and have been shown to cause profound decreases in concentrations of other protease inhibitors, which can result in virological failure and resistance development (CYP450 enzyme induction).
Effekten af svært nedsat leverfunktion på farmakokinetikken for darunavir er ikke blevet undersøgt (se pkt.
The effect of severe hepatic impairment on the pharmacokinetics of darunavir has not been studied (see sections 4.2, 4.3 and 4.4).
30 filmovertrukne tabletter: EU/1/17/1249/009 90 filmovertrukne tabletter: EU/1/17/1249/010
30 film-coated tablets: EU/1/17/1249/009 90 film-coated tablets: EU/1/17/1249/010
For oplysninger om cobicistat, se produktresuméet for cobicistat.
For information on cobicistat, consult the cobicistat Summary of Product Characteristics.
Interaktion Geometrisk middelændring
Interaction Geometric mean change (%)
Hvis efavirenz skal anvendes i kombination med darunavir, bør der anvendes et regime med darunavir/ritonavir 600/100 mg to gange daglig.
If efavirenz is to be used in combination with darunavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used.
Kontakt din læge, hvis du får hududslæt.
Please contact your doctor whenever you develop a rash.
800 mg darunavir/100 mg ritonavir en gang dagligt ritonavir oral opløsning: 80 mg/ml
800 mg darunavir/100 mg ritonavir once daily ritonavir oral solution: 80 mg/ml
knogleskørhed - nedsættelse af skjoldbruskkirtlens funktion.Dettekan ses ved en blodprøve - forhøjet blodtryk, rødme - røde eller tørre øjne - feber, hævede ben på grund af væske, utilpashed, irritabilitet, smerte - symptomer på infektion, herpes simplex - impotens, større bryster - søvnproblemer, søvnighed, depression, angst, unormale drømme, nedgang i seksuallyst.
This can be seen in a blood test. high blood pressure, flushing red or dry eyes fever, swelling of lower limbs due to fluids, malaise, irritability, pain symptoms of infection, herpes simplex erectile dysfunction, enlargement of breasts sleeping problems, sleepiness, depression, anxiety, abnormal dreams, decrease in sexual drive
Darunavir skal altid gives oralt med cobicistat eller lavdosis ritonavir som en farmakokinetisk forstærker og i kombination med andre antiretrovirale lægemidler (se pkt.
Darunavir must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products (see section 5.2).
- ART-erfarne uden mutationer associeret med darunavirresistens (DRV-RAMs), og som har plasma hiv-1-RNA < 100.000 kopier/ml og CD4+-celletal ≥ 100 x 6 celler/l.
ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
12 ART-naive hiv-1-smittede pædiatriske patienter i alderen 12 til 17 år med en legemsvægt på mindst 40 kg, som fik darunavir tabletter sammen med lavdosis ritonavir en gang daglig i kombination med andre antiretrovirale lægemidler (se pkt.
12 ART-naïve HIV-1 infected paediatric patients aged from 12 to 17 years and weighing at least 40 kg who received darunavir tablets with low dose ritonavir once daily in combination with other antiretroviral agents (see section 5.1).
Hos kvinder, der fik 600/100 mg darunavir/ritonavir to gange dagligt i andet trimester af graviditeten, var de gennemsnitlige intraindividuelle værdier for Cmax, AUC12t og Cmin for total-darunavir hhv. 28 %, 26 % og 26 % lavere i forhold til post partum.
In women receiving darunavir/ritonavir 600/100 mg twice daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC12h and Cmin were 28%, 26% and 26% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC12h and Cmin values were 18%, 16% lower and 2% higher, respectively, as compared with postpartum.
Co-administration af boostet darunavir og dapoxetin er kontraindiceret.
Co-administration of boosted darunavir with dapoxetine is contraindicated.
Samtidig administration af naturlægemidler, der indeholder perikon (Hypericum perforatum) (se pkt.
Co-administration with herbal preparations containing St John's wort (Hypericum perforatum) (see section 4.5).
Co-administration af darunavir/ritonavir med lægemidler, der især metaboliseres af CYP3A og/eller CYP2D6 eller transporteres af P-gp, kan forårsage øget systemisk eksponering for sådanne lægemidler, hvilket kan øge eller forlænge både den terapeutiske virkning og bivirkninger.
Co-administration of darunavir/ritonavir with medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
EU/1/17/1249/009 30 filmovertrukne tabletter EU/1/17/1249/010 90 filmovertrukne tabletter
EU/1/17/1249/009 30 film-coated tablets EU/1/17/1249/010 90 film-coated tablets
Klinisk monitoring anbefales ved administration af boostet darunavir sammen med disse analgetika.
Clinical monitoring is recommended when co-administering boosted darunavir with these analgesics.
Nukleosid-revers-transkriptase-hæmmere (NRTI'er) Didanosin
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine
UROLOGISKE LÆGEMIDLER Fesoterodin
UROLOGICAL DRUGS Fesoterodine Solifenacin